文献速递新发突发、热带与寄生虫病

TAK-003对无症状登革感染估计效力:DEN-301试验分析

Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America.
PubMed 文献 · J Infect Dis · 2025-01-01

DEN-301是一项3期试验,4至16岁参与者间隔3个月接种2剂TAK-003或安慰剂。探索性分析用三种算法评估3765名参与者无症状感染疫苗效力,接种后4至9个月算法1的VE为51.1%(95%CI 30.4%-65.6%),基线血清阳性者中较高,且随时间逐渐下降。

要点

  • 三种无症状感染算法所得VE不一致,提示准确评估无症状感染VE存在挑战
  • 接种后4至9个月算法1的VE为51.1%(95%CI 30.4%-65.6%)
  • VE从接种后4至9个月到9至15个月、再到15至27个月逐渐下降

核心结论

  • TAK-003在接种后最初数月对无症状登革感染有中等影响,主要用于基线血清阳性参与者。
  • VE算法间的变异性表明准确评估无症状感染VE存在挑战。

研究设计与样本

  • DEN-301(NCT02747927)为3期试验,4至16岁参与者间隔3个月接种2剂TAK-003或安慰剂。
  • 本探索性分析使用试验期间测定的中和抗体(NAb),分析3765名参与者的NAb。
  • 评估三种无症状感染算法:⑴NAb 4倍升高;⑵NAb 4倍升高且最低滴度40;⑶NAb 4倍升高且最低滴度为定量下限的4倍。
  • 分析接种后4至9个月、9至15个月、15至27个月三个时间段。

主要发现

  • 接种后4至9个月,算法1、2、3的无症状感染VE分别为51.1%(95%CI 30.4%-65.6%)、36.1%(95%CI 6.7%-56.3%)、27.3%(95%CI -8.2%至51.2%)。
  • 基线血清阳性者中,算法1、2、3的VE分别为54.8%(95%CI 28.8%-71.3%)、47.9%(95%CI 16.8%-67.4%)、44.3%(95%CI 9.9%-65.6%)。
  • 基线血清阴性者中,算法1、2、3的VE分别为44.4%(95%CI 2.1%-68.4%)、4.6%(95%CI -85.1%至50.8%)、-29.3%(95%CI -172.1%至38.6%)。
  • VE从接种后4至9个月到9至15个月、从9至15个月到15至27个月逐渐下降。

关键数值与推荐

  • 无症状感染算法1:NAb 4倍升高。
  • 无症状感染算法2:NAb 4倍升高且最低滴度40。
  • 无症状感染算法3:NAb 4倍升高且最低滴度为定量下限的4倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出目前尚无公认的无症状感染定义,故评估了三种算法。
  • 原文结论指出VE算法间的变异性表明准确评估无症状感染VE存在挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: TAK-003 has been shown to be well tolerated and effective against symptomatic dengue disease and hospitalization, irrespective of baseline serostatus. Most infections are asymptomatic/subclinical. This study assessed whether TAK-003 could protect against asymptomatic/subclinical infections by evaluating increased neutralizing antibody (NAb) titers after natural infection. METHODS: DEN-301 (NCT02747927) is a phase 3 trial among 4- to 16-year-old participants who received 2 doses of TAK-003 or placebo 3 months apart. These exploratory analyses used NAb measured during the trial. As no well-accepted definition for asymptomatic infection exists, 3 algorithms were evaluated: (1) 4-fold increase in NAb, (2) 4-fold increase in NAb and a minimum titer of 40, and (3) 4-fold increase in NAb and a minimum titer of 4-fold lower limit of quantification. Months 4 to 9, months 9 to 15, and months 15 to 27 after first vaccination were analyzed. RESULTS: NAbs from 3765 participants were analyzed. From months 4 to 9, vaccine efficacy (VE) against asymptomatic infection was 51.1% (95% CI, 30.4%-65.6%), 36.1% (95% CI, 6.7%-56.3%), and 27.3% (95% CI, -8.2% to 51.2%) for algorithms 1, 2, and 3, respectively. VE per algorithms 1, 2, and 3 was 54.8% (95% CI, 28.8%-71.3%), 47.9% (95% CI, 16.8%-67.4%), and 44.3% (95% CI, 9.9%-65.6%) in participants with baseline seropositivity and 44.4% (95% CI, 2.1%-68.4%), 4.6% (95% CI, -85.1% to 50.8%), and -29.3% (95% CI, -172.1% to 38.6%) in those with baseline seronegativity. VE against asymptomatic infection gradually decreased from months 4 to 9 to months 9 to 15 and from months 9 to 15 to months 15 to 27. CONCLUSIONS: The variability in VE algorithms indicates challenges in accurately assessing VE against asymptomatic infections. TAK-003 had a modest impact on asymptomatic dengue infections in the first months postvaccination, mainly in participants with baseline seropositivity.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. El Hindi T, Alera MT, Bravo L, et al. Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America. J Infect Dis. 2025. PMID: 40100744. doi:10.1093/infdis/jiaf145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。